Mitochondrial dysfunction sits at the intersection of nearly every major age-related condition researchers study today — from cardiovascular decline to neurodegenerative disease to metabolic failure. SS-31, also known as Elamipretide or MTP-131, has emerged as one of the most compelling compounds in this space. Unlike most peptides that act at the receptor level, SS-31 works inside the cell, directly targeting the mitochondrial inner membrane. This article breaks down what the current literature says.
What Is SS-31?
SS-31 (Szeto-Schiller peptide 31) is a synthetic tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH₂. It was originally developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College as part of a broader effort to create cell-permeable peptides that could concentrate in mitochondria.
What sets SS-31 apart from most research compounds is its unique mechanism: it selectively binds to cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a critical structural role in the electron transport chain — the cellular machinery that produces ATP. When cardiolipin becomes oxidized or disorganized (a hallmark of aging and disease states), mitochondrial efficiency drops dramatically. SS-31 appears to stabilize this relationship, restoring electron transport chain architecture and reducing oxidative stress at the mitochondrial level.
The compound is also known by its clinical development name Elamipretide, under which it has been studied by Stealth BioTherapeutics in Phase II and Phase III trials for conditions including heart failure, Barth syndrome, and primary mitochondrial myopathy.
Research Overview
Cardiac protection: A landmark study published in the Journal of the American College of Cardiology demonstrated that SS-31 significantly reduced infarct size in animal models of myocardial ischemia-reperfusion injury. (PubMed: PMID 17478154)
Aging and skeletal muscle: Research from the Buck Institute demonstrated that SS-31 treatment in aged mice restored mitochondrial morphology in skeletal muscle and improved physical performance metrics. (PubMed: PMID 30266827)
Kidney protection: Multiple preclinical studies have examined SS-31 in the context of acute kidney injury, showing reduced tubular cell apoptosis and improved renal function markers. (PubMed: PMID 24231452)
Neurological research: A growing body of work examines SS-31 in models of Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury — all conditions where mitochondrial dysfunction is a recognized pathological driver. (Google Scholar: SS-31 neurodegeneration)
Community discussion: (Reddit: r/Peptides — SS-31 threads)
Potential Benefits Studied
- Mitochondrial membrane stabilization — SS-31 binds cardiolipin and restores inner membrane integrity, directly improving electron transport chain efficiency
- Reduced oxidative stress — by improving ETC coupling, SS-31 reduces electron leak and mitochondrial ROS production, a key driver of cellular aging
- Cardiac protection — preclinical and early clinical data show reduced ischemia-reperfusion injury and improved cardiac output in heart failure models
- Skeletal muscle and exercise capacity — aged animal models show improved muscle mitochondrial morphology and physical performance with SS-31 treatment
- Renal protection — multiple studies demonstrate preserved tubular cell function and reduced acute kidney injury markers
- Neuroprotection — emerging research links mitochondrial support from SS-31 to reduced neuronal apoptosis in models of neurodegeneration
- Metabolic support — improved mitochondrial function may underpin broader effects on insulin sensitivity and metabolic rate observed in some research models
Dosage & Administration
In published clinical research, Elamipretide has been administered primarily via subcutaneous injection. The MMPOWER-3 trial used a dose of 40 mg/day via subcutaneous infusion over 52 weeks. In preclinical and peptide research community contexts, subcutaneous dosing protocols typically reference a range of 1–10 mg per injection, with frequency ranging from daily to three times per week. SS-31 requires reconstitution with bacteriostatic water when supplied in lyophilized powder form.
Where to Find SS-31 10MG
Researchers looking for SS-31 for laboratory and research purposes can find it at Combat Research — SS-31 10MG. Combat Research supplies research-grade peptides tested for purity and identity.
Conclusion
SS-31 occupies a genuinely unique position in peptide research. While most compounds in this space target surface receptors or circulating growth factors, SS-31 acts inside the cell — at the mitochondrial membrane where energy is actually made. The clinical trial history through Stealth BioTherapeutics provides a meaningful safety and pharmacokinetic reference point that most research peptides lack entirely. For researchers focused on aging biology, cardiac research, metabolic health, or neuroprotection, SS-31 represents one of the most mechanistically well-grounded compounds currently available.
Disclaimer
This article is for educational and research purposes only. SS-31 / Elamipretide is not approved by the FDA for human use outside of clinical trials. This is not medical advice. Always consult a qualified healthcare professional before using any research compound. Combat Research sells SS-31 strictly for laboratory research use.
